Abstract
Within the recent years, RNA interference (RNAi) has become an almost standard method for in vitro knockdown of any target gene of interest. Now, one major focus is to further explore its potential therapeutic use. From the mechanism, it becomes clear that small interfering RNAs (siRNAs) play a pivotal role in triggering RNAi. This chapter describes the in vivo application of targeted non-virally delivered synthetic bcr-abl siRNA in a female patient with recurrent Philadelphia chromosome positive chronic myeloid leukemia (CML) resistant to imatinib (Y253F mutation) and chemotherapy after allogeneic hematopoietic stem cell transplantation. A remarkable inhibition of the overexpressed bcr-abl oncogene resulting in increased apoptosis of CML cells was found. In vivo siRNA application was well tolerated without any clinically adverse events. The current findings imply that the clinical application of synthetic siRNA is feasible and safe and has real potential for genetic-based therapies using synthetic non-viral carriers.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Goldmann JM, Melo JV (2003) Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 349:1451–1461
Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343–3356
Simanovsky M, Berlinsky S, Sinai P, Leiba M, Nagler A, Galski H (2008) Phenotypic and gene expression diversity of malignant cells in human blast crisis chronic myeloid leukemia. Differentiation 76:908–922
Radich JP, Dai H, Mao M et al (2006) Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A 103:2794–2799
Lage H (2005) Potential applications of RNA interference technology in the treatment of cancer. Future Oncol 1:103–113
Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T (2001) Duplexes of 21- nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411:494–498
Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC (1998) Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 391:806–811
Burnett JC, Rossi JJ (2012) RNA-based therapeutics: current progress and future prospects. Chem Biol 19:60–71
Mittal V (2004) Improving the efficiency of RNA interference in mammals. Nat Rev Genet 5:355–365
Kanasty R, Dorkin JR, Vegas A, Anderson D (2013) Delivery materials for siRNA therapeutics. Nat Mater 12:967–977
Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD (2003) Asymmetry in the assembly of the RNAi enzyme complex. Cell 115:199–208
Elmaagacli AH, Koldehoff M, Peceny R et al (2005) WT1 and BCR-ABL specific small interfering RNA have additive effects in the induction of apoptosis in leukemic cells. Haematologica 90:326–334
Koldehoff M, Kordelas L, Beelen DW, Elmaagacli AH (2010) Small interfering RNA against BCR-ABL transcripts sensitize mutated T315I cells to nilotinib. Haematologica 95:388–397
Koldehoff M, Zakrzewski JL, Beelen DW, Elmaagacli AH (2013) Additive antileukemia effects by GFI1B- and BCR-ABL-specific siRNA in advanced phase chronic myeloid leukemic cells. Cancer Gene Ther 20:421–427
Gratwohl A, Baldomero H, Horisberger B, Schmid C, Passweg J, Urbano-Ispizua A (2002) Current trends in hematopoietic stem cell transplantation in Europe. Blood 100:2374–2386
Goldman J, Gordon M (2006) Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter? Leuk Lymphoma 47:1–7
Dass CR (2004) Lipoplex-mediated delivery of nucleic acids: factors affecting in vivo transfection. J Mol Med 82:579–591
Fattal E, Couvreur P, Dubernet C (2004) “Smart” delivery of antisense oligonucleotides by anionic pH-sensitive liposomes. Adv Drug Del Rev 56:931–946
Koldehoff M, Steckel NK, Beelen DW, Elmaagacli AH (2007) Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia. Clin Exp Med 7:47–55
de Fougerolles A, Vornlocher HP, Maraganore J, Liebermann J (2007) Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6:443–453
Kawakami S, Hashida M (2007) Targeted delivery systems of small interfering RNA by systemic administration. Drug Metab Pharmacokinet 22:142–151
Soutschek J, Akinc A, Bramlage B et al (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173–178
Morrissey DV, Lockridge JA, Shaw L et al (2005) Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002–1007
Song E, Zhu P, Lee S-K et al (2005) Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 23(7):09–717
Sezaki H, Hashida M (1984) Macromolecule-drug conjugates in targeted cancer chemotherapy. Crit Rev Ther Drug Carrier Syst 1:1–38
Scherr M, Battmer K, Winkler T, Heidenreich O, Ganser A, Eder M (2003) Specific inhibition of BCR-ABL gene expression by small interfering RNA. Blood 101:1566–1569
Sewell KL, Geary RS, Baker BF et al (2002) Phase I trial of ISIS 104838, a 2′-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-α. J Pharmacol Exp Ther 303:1334
O’Brian SM, Cunningham CC, Golenkov AK, Turkina AG, Novick SC, Rai KR (2005) Phase I and II multicenter study of oblimersen sodium a Bcl-2 antisense oligonucleotide in patients with advanced chronic lymphocytic leukaemia. J Clin Oncol 23:7697–7702
Kretschmer-Kazemi Far R, Sczakiel G (2003) The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides. Nucleic Acids Res 31:4417–4424
Advani R, Peethambaram P, Lum BL et al (2004) A phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with ovarian carcinoma. Cancer 100:321–326
Marcucci G, Byrd JC, Dai G et al (2003) Phase 1 and pharmacodynamic studies of G3139, a BCL-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed leukemia. Blood 101:425–432
Goldman J (2004) Monitoring minimal residual disease in BCR-ABL-positive chronic myeloid leukaemia in the imatinib era. Curr Opin Hematol 12:33–39
Branford S, Rudzki Z, Walsh S et al (2002) High frequency of point mutation clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukaemia or Ph-positive acute lymphoblastic leukaemia who develop imatinib (STI571) resistance. Blood 99:3472–3475
Branford S, Rudzki Z, Walsch S et al (2003) Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276–283
Wohlbold L, van der Kuip H, Miething C, Vornlocher HP, Knabbe C, Duyster J, Aulitzky WE (2003) Inhibition of BCR-ABL gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 102:2236–2269
Wilda M, Fuchs U, Wössmann W, Borkhardt A (2002) Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference. Oncogene 21:5716–5724
Withey JM, Marley SB, Kaeda J, Harvey AJ, Crompton MR, Gordon MY (2005) Targeting primary human leukaemia cells with RNA interference: BCR-ABL targeting inhibits myeloid progenitor self-renewal in chronic myeloid leukaemia cells. Br J Haematol 129:377–380
Guo W, Lee RJ (2000) Efficient gene delivery using anionic liposome-complexed polyplexes (LPDII). Biosci Rep 20:419–432
Patil SD, Rhodes DG, Burgess DJ (2005) Biophysical characterization of anionic lipoplexes. Biochim Biophys Acta 1711:1–11
Dias N, Stein CA (2002) Antisense oligonucleotides: basic concepts and mechanisms. Mol Cancer Ther 1:347–355
Hornung V, Guenthner-Biller M, Bourquin C et al (2005) Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat Med 11:263–270
Aigner A (2007) Application of RNA interference: current state and prospects for siRNA-based strategies in vivo. Appl Microbiol Biotechnol 76:9–21
Martínez T, Wright N, López-Fraga M, Jiménez AI, Pañeda C (2013) Silencing human genetic diseases with oligonucleotide-based therapies. Hum Genet 132:481–493
Acknowledgements
The author would like to thank Katja Ahrens, Melanie Kroll, Silke Gottwald, Ines Riepenhoff, and Christiane Schary for their excellent technical execution of the PCR analyses.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Koldehoff, M. (2015). Targeting bcr-abl Transcripts with siRNAs in an Imatinib-Resistant Chronic Myeloid Leukemia Patient: Challenges and Future Directions. In: Sioud, M. (eds) RNA Interference. Methods in Molecular Biology, vol 1218. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1538-5_17
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1538-5_17
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1537-8
Online ISBN: 978-1-4939-1538-5
eBook Packages: Springer Protocols